Motif Neurotech, Inc. | Therapeutic Brain-Computer Interface Manufacturer

admin 32 2026-05-04 16:35:59

Company Profile

Motif Neurotech, Inc. is a US-based manufacturer of implantable therapeutic brain-computer interfaces (BCI), headquartered in Houston, Texas. Founded in 2022 by Dr. Jacob Robinson (CEO, Rice University professor), Dr. Sameer Sheth (CMO, Baylor College of Medicine neurosurgeon), Dr. Sunil Sheth (interventional neurologist), and Kaiyuan Yang (Rice University professor of electrical and computer engineering), the privately held company has raised USD 18.75 million in Series A financing led by Arboretum Ventures. Motif is supported by non-dilutive funding from DARPA, NIH BRAIN Initiative, and ARPA-H.

Core Products ＆ Technologies

DOT™ Digitally Programmable Over-brain Therapeutic

• Implantable Microstimulator: Battery-free, leadless implant placed above the dura in a minimally invasive outpatient procedure without exposing or touching the brain
• Wireless Power ＆ Control: Patented magnetoelectric wireless power transfer technology invented at Rice University; powered and controlled by a wearable headset
• Closed-Loop Capability: System designed to record neural biomarkers and adapt stimulation patterns, enabling personalized, responsive therapy over time
• Mental Health Targeting: Delivers gentle electrical stimulation to the prefrontal cortex to restore healthy brain circuit activity, countering rumination-linked Default Mode Network dominance by activating the Central Executive Network

Clinical Development

• RESONATE Early Feasibility Study: FDA IDE approved April 14, 2026; prospective study evaluating safety and viability of the DOT system over 12 months in adults with treatment-resistant depression who have failed two or more medications
• Clinical Sites: Eight leading US institutions including Baylor College of Medicine, Massachusetts General Brigham, Emory Healthcare, UT Health Houston, University of Iowa, University of Utah Health, New York University, and Brain Health Consultants (Houston)
• Principal Investigator: Dr. Sameer Sheth, Professor of Neurosurgery at Baylor College of Medicine and Director of the Cain Foundation Labs at Texas Children's Hospital
• First-in-Human Milestone: Completed first-in-human implantation in 2023; intraoperative demonstration confirmed safe motor cortex stimulation with finger movement response

Strategic Technology Partnership

• MintNeuro Alliance (April 2026): Multi-year commercial supply agreement integrating MintNeuro's purpose-built neural sensing and stimulation integrated circuits into Motif's clinical device roadmap, advancing closed-loop therapeutic capabilities and real-time response monitoring

Market Position ＆ Certifications

Motif Neurotech holds a pioneering position in the therapeutic BCI market for mental health, competing with Neuralink, Abbott (DBS for TRD), Brainsway (TMS), and Neuronetics. Key strengths include:

• Fastest BCI regulatory timeline: Achieved FDA IDE approval just four years after founding — a record for an implantable BCI company with a novel device
• Minimally invasive design: Outpatient procedure with no brain exposure, no batteries, and no leads; cosmetically invisible implant
• Non-dilutive funding base: Supported by DARPA, NIH BRAIN Initiative, ARPA-H EVIDENT program ($45 million award), and UK ARIA, validating scientific and clinical merit
• Patient-centric co-design: Products developed with input from a community advisory board of individuals with lived mental health experience
• Expansion pipeline: Exploring applications in bipolar disorder, Alzheimer's disease, obsessive-compulsive disorder, and substance use disorder

Corporate Timeline

2022 — Founded in Houston, Texas by Jacob Robinson, Sameer Sheth, Sunil Sheth, and Kaiyuan Yang
2023 — Completed first-in-human implantation of DOT microstimulator; demonstrated safe brain stimulation during tumor resection surgery at Baylor College of Medicine
2024 — Closed oversubscribed USD 18.75 million Series A financing led by Arboretum Ventures
2025 — Hired Steven Goetz as CTO (former Medtronic Neuromodulation); launched patient registry for treatment-resistant depression; published large animal studies exceeding 30 days of continuous operation
2026 — Received FDA IDE approval for RESONATE trial (April 14); announced strategic partnership with MintNeuro for neural interface chips (April 22); selected for ARPA-H EVIDENT behavioral health initiative with $45 million funding

Target Markets ＆ Applications

• Treatment-Resistant Depression (TRD): Primary indication for adults who have failed two or more antidepressant regimens
• Bipolar Disorder: Planned expansion into mood stabilization for bipolar patients
• Alzheimer's Disease: Exploring neuromodulation for cognitive enhancement and symptom management
• Obsessive-Compulsive Disorder (OCD): Potential application for circuit-based OCD therapy
• Substance Use Disorder: Investigating craving reduction and relapse prevention through targeted brain stimulation
• Global Mental Health: Long-term vision to make brain pacemakers as routine as cardiac pacemakers for psychiatric conditions